Evidence map›Paper›PMID 30986227›Full record

Trial reportPloS one2019

Tuberculosis incidence among infected contacts detected through contact tracing of smear-positive patients.

Mario Martin-Sanchez, Silvia Brugueras, Anna de Andrés, Pere Simon, Pilar Gorrindo, Miriam Ros, Eva Masdeu, Joan-Pau Millet, Joan A Caylà, Àngels Orcau and 1 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mario Martin-SanchezEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0002-2221-5331
Silvia BruguerasEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0001-6439-0050
Anna de AndrésEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0001-6980-2050
Pere SimonEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0002-5057-7583
Pilar GorrindoEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0003-0419-0641
Miriam RosEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0002-3659-8222
Eva MasdeuEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.
Joan-Pau MilletEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.ORCID 0000-0003-0200-2459
Joan A CaylàFoundation of the Tuberculosis Research Unit of Barcelona (fuiTB), Barcelona, Spain.ORCID 0000-0003-3891-111X
Àngels OrcauEpidemiology Service, Agència de Salut Pública de Barcelona (ASPB), Barcelona, Spain.
Contact Tracing Group of the Tuberculosis Investigation Unit of Barcelona
Agencia de Salud Pública de Barcelona · ESCentre for Biomedical Network Research on Rare Diseases · ESUniversitat Autònoma de Barcelona · ESUniversitat Pompeu Fabra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe contacts of people with pulmonary tuberculosis (PTB) have a high risk of becoming infected and developing tuberculosis (TB). Our aim was to determine the incidence of TB and its risk factors in a cohort of contacts with latent TB infection (LTBI) detected through contact tracing of smear-positive PTB cases. METHODS AND

findingsWe performed a population-based retrospective cohort study including contacts that had LTBI, and were contacts of people with PTB who started treatment between 2008 and 2014. We followed up contacts until they developed TB or until the end date for follow-up (31st December 2016). We used Kaplan-Meier curves to compute incidence at 2 and 5 years, and Cox regression to compute hazard ratios (HR) and their 95% confidence intervals (CI). We analyzed 3097 close contacts of 565 PTB cases. After exclusion of 81 co-prevalent TB cases, 953 contacts had LTBI, of which 14 developed TB. Their risk of developing TB after two and five years was 0.7% (CI: 0.3-1.6) and 1.8% (CI: 1.1-3.1) respectively. Contacts who had not been referred for LTBI treatment had a 1.0% (CI: 0.2-4.0) risk at 5 years. Risk of developing TB at 5 years was 1.2% (CI: 0.5-3.0) among people who completed treatment, and 11.1% (CI: 5.1-23.3) for those who did not. Risk factors for TB were not completing LTBI treatment (HR 9.4, CI: 2.9-30.8) and being female (HR 3.5, CI: 1.1-11-3).

conclusionsLTBI treatment plays a fundamental role in decreasing the risk of developing TB. It is necessary to achieve a maximum contact tracing coverage and the highest possible compliance with LTBI treatment.

Indexed as

AdolescentAdultChildChild, PreschoolFemaleFollow-Up StudiesHumansIncidenceLatent TuberculosisMaleMiddle AgedRetrospective StudiesTuberculosis, Pulmonary

Identifiers

PMID30986227
PMCPMC6464217
OpenAlexW2937994735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.